Oppenheimer Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $404K | Sell |
2,204
-808
| -27% | -$149K | ﹤0.01% | 914 |
|
|
2025
Q4 | $530K | Buy |
+3,012
| New | +$492K | 0.01% | 812 |
|
|
2024
Q4 | – | Sell |
-35,928
| Closed | -$6.96M | – | 1157 |
|
|
2024
Q3 | $6.96M | Sell |
35,928
-839
| -2% | -$176K | 0.08% | 255 |
|
|
2024
Q2 | $8.52M | Buy |
36,767
+2,787
| +8% | +$606K | 0.11% | 218 |
|
|
2024
Q1 | $7.33M | Sell |
33,980
-4,619
| -12% | -$1.08M | 0.11% | 214 |
|
|
2023
Q4 | $9.99M | Sell |
38,599
-2,796
| -7% | -$687K | 0.14% | 180 |
|
|
2023
Q3 | $10.6M | Buy |
41,395
+123
| +0.3% | +$32.9K | 0.16% | 151 |
|
|
2023
Q2 | $11.8M | Sell |
41,272
-410
| -1% | -$122K | 0.17% | 142 |
|
|
2023
Q1 | $11.6M | Sell |
41,682
-494
| -1% | -$137K | 0.18% | 140 |
|
|
2022
Q4 | $11.7M | Sell |
42,176
-5,023
| -11% | -$1.42M | 0.19% | 147 |
|
|
2022
Q3 | $12.6M | Buy |
47,199
+1,407
| +3% | +$299K | 0.22% | 111 |
|
|
2022
Q2 | $9.34M | Sell |
45,792
-61
| -0.1% | -$12.5K | 0.16% | 159 |
|
|
2022
Q1 | $9.66M | Buy |
45,853
+275
| +0.6% | +$59.8K | 0.14% | 181 |
|
|
2021
Q4 | $10.9M | Sell |
45,578
-6,960
| -13% | -$1.79M | 0.15% | 168 |
|
|
2021
Q3 | $14.9M | Buy |
52,538
+2,575
| +5% | +$844K | 0.21% | 114 |
|
|
2021
Q2 | $17.3M | Buy |
49,963
+3,626
| +8% | +$1.1M | 0.25% | 91 |
|
|
2021
Q1 | $13M | Buy |
46,337
+2,577
| +6% | +$695K | 0.2% | 123 |
|
|
2020
Q4 | $10.7M | Buy |
43,760
+3,380
| +8% | +$872K | 0.18% | 141 |
|
|
2020
Q3 | $11.5M | Buy |
40,380
+2,015
| +5% | +$562K | 0.22% | 114 |
|
|
2020
Q2 | $10.3M | Buy |
38,365
+4,907
| +15% | +$1.48M | 0.21% | 121 |
|
|
2020
Q1 | $10.6M | Buy |
33,458
+2,623
| +9% | +$796K | 0.26% | 100 |
|
|
2019
Q4 | $9.15M | Buy |
30,835
+285
| +0.9% | +$79.1K | 0.19% | 134 |
|
|
2019
Q3 | $7.11M | Buy |
30,550
+2,693
| +10% | +$627K | 0.16% | 169 |
|
|
2019
Q2 | $6.51M | Buy |
27,857
+5,526
| +25% | +$1.28M | 0.14% | 181 |
|
|
2019
Q1 | $5.28M | Buy |
22,331
+2,932
| +15% | +$923K | 0.12% | 212 |
|
|
2018
Q4 | $5.84M | Buy |
19,399
+695
| +4% | +$222K | 0.14% | 170 |
|
|
2018
Q3 | $6.61M | Sell |
18,704
-1,321
| -7% | -$455K | 0.15% | 169 |
|
|
2018
Q2 | $5.81M | Buy |
20,025
+2,697
| +16% | +$758K | 0.14% | 179 |
|
|
2018
Q1 | $4.75M | Buy |
17,328
+2,483
| +17% | +$771K | 0.12% | 217 |
|
|
2017
Q4 | $4.65M | Hold |
14,845
| – | – | 0.12% | 189 |
|
|
2017
Q3 | $4.65M | Buy |
14,845
+236
| +2% | +$69.9K | 0.12% | 191 |
|
|
2017
Q2 | $3.96M | Sell |
14,609
-655
| -4% | -$173K | 0.11% | 218 |
|
|
2017
Q1 | $4.17M | Buy |
+15,264
| New | +$4.32M | 0.12% | 199 |
|
Other funds holding BIIB
VCM
VPM
Oppenheimer Asset Management's BIIB Position: Q1 2026 in Review
Oppenheimer Asset Management reduced its Biogen (BIIB) stake by 27% in Q1 2026, selling an estimated $149K and leaving 2,204 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #914.
Oppenheimer Asset Management first reported a position in BIIB in Q1 2017 and has held it in 33 quarters since. The position peaked at $17.3M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Oppenheimer Asset Management held 2,204 shares of Biogen worth $404K as of Q1 2026.
- Oppenheimer Asset Management sold 808 Biogen shares in Q1 2026, an estimated $149K.
- Biogen made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q1 2026, its #914 holding.
- Oppenheimer Asset Management first reported a position in Biogen in Q1 2017 and has held it in 33 quarters since.
- Oppenheimer Asset Management's Biogen position peaked at $17.3M in Q2 2021.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.